XML 18 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Operating activities:    
Net income (loss) $ (67,381) $ 5,878
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation 4,858 3,990
Amortization of patents 895 802
Amortization of premium on investments, net 1,845 3,558
Amortization of debt issuance costs 853 797
Amortization of convertible senior notes discount 16,364 15,163
Amortization of long-term financing liability for leased facility 0 3,352
Stock-based compensation expense 62,327 42,170
Gain on investment in Regulus Therapeutics, Inc. 0 (374)
Non-cash losses related to patents, licensing and property, plant and equipment 415 129
Changes in operating assets and liabilities:    
Contracts receivable 46,193 57,428
Inventories 915 985
Other current and long-term assets (5,177) (39,371)
Accounts payable (14,239) (10,030)
Accrued compensation (10,062) (13,888)
Accrued liabilities and deferred rent (8,218) (1,149)
Deferred contract revenue 483,814 55,588
Net cash provided by operating activities 513,402 125,028
Investing activities:    
Purchases of short-term investments (648,902) (347,916)
Proceeds from the sale of short-term investments 364,048 202,475
Purchases of property, plant and equipment (8,977) (9,453)
Acquisition of licenses and other assets, net (1,854) (1,593)
Proceeds from the sale of Regulus Therapeutics stock 0 2,507
Net cash provided by (used in) investing activities (295,685) (153,980)
Financing activities:    
Proceeds from equity awards 10,178 9,927
Stock issuance costs paid 0 (1,031)
Principal payments on debt and capital lease obligations 0 (3,278)
Net cash provided by financing activities 458,143 77,258
Net increase in cash and cash equivalents 675,860 48,306
Cash and cash equivalents at end of period 805,490 132,991
Supplemental disclosures of cash flow information:    
Interest paid 4,753 3,607
Cash and cash equivalents at beginning of period 129,630 84,685
Supplemental disclosures of non-cash investing and financing activities:    
Amounts accrued for capital and patent expenditures 2,645 1,705
Unpaid deferred offering costs 0 473
Novartis [Member]    
Financing activities:    
Proceeds from issuance of common stock 0 71,640
Biogen [Member]    
Financing activities:    
Proceeds from issuance of common stock $ 447,965 $ 0